Pasithea Therapeutics News

Express News | Pasithea Therapeutics Corp - Src Recommends Escalation to 15Mg Dose Level

BreakingsNov 20 20:02

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation From Its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswireNov 20 20:02

Express News | Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer

BreakingsNov 20 20:02

10-Q: Q3 2024 Earnings Report

SECNov 14 05:37 · Announcements

Pasithea Therapeutics Files to Sell 3.74M Shares of Common Stock for Holders

Seeking AlphaOct 8 04:52

Pasithea Therapeutics Priced $5M Private Placement of $1.2M Shares At $4.10/Share to Advance Next-Gen Cancer Treatments

BenzingaSep 27 15:03

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswireSep 27 06:44

Express News | Pasithea Therapeutics Announces $5 Million Private Placement Priced at-the-Market Under Nasdaq Rules

BreakingsSep 27 06:44

Sector Update: Health Care

MT NewswiresSep 27 03:24

12 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaSep 27 00:31

Crude Oil Down Over 2%; US Initial Jobless Claims Fall

BenzingaSep 27 00:01

Trending Stocks Today | Fangdd Network Shoots up 154%

September 26th - US stocks trending in regular trading hours.Gainers: $Fangdd Network(DUO.US)$ soars 154% to $1.27 with a turnover of $162.19 million. $TELESIS BIO(TBIO.US)$ shoots up 65.95% to $3.85

Futu NewsSep 26 22:45

Nasdaq Gains Over 1%; Micron Posts Upbeat Q4 Results

BenzingaSep 26 21:48

Why Is Pasithea Therapeutics Stock Surging On Thursday?

BenzingaSep 26 20:56

Top Premarket Gainers

MT NewswiresSep 26 20:03

Market-Moving News for September 26th

BenzingaSep 26 19:59

Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety

MT NewswiresSep 26 19:56

Express News | Pasithea Therapeutics Corp - No Treatment-Related Adverse Events or Dose-Limiting Toxicities Observed

BreakingsSep 26 19:02

Express News | Pasithea Therapeutics Corp - Patient With Stage 3 Colon Cancer Achieves Prolonged Stable Disease

BreakingsSep 26 19:02

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data From Its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswireSep 26 19:02